September 2007 DSM
DSM accelerates shift to Life Sciences and Materials Sciences company and raises growth targets
|Today, the newly composed Managing Board of Royal DSM N.V. presents the conclusions from its early, mid-term evaluation of the Vision 2010 - Building on Strengths strategy:|
|・||DSM accelerates the shift to a Life Sciences (Nutrition and Pharma) and Materials Sciences (Performance Materials) company:|
|-||this shift strongly positions DSM to meet the needs of tomorrow’s society in areas such as nutrition and health as well as advanced materials to improve the quality of life and the environment|
|-||as a consequence DSM initiates a divestment program for non-core businesses and|
|-||steps-up search for acquisitions in core business areas to achieve external growth|
new growth targets
- organic sales growth target raised to >5% per year
- raised sales target for China in 2010 from USD 1 billion to USD 1.5 billion
|・||Commitment to deliver EUR 1 billion additional sales from innovation by 2010|
|・||Dividend increase of 20% per share will be recommended at AGM in March 2008|
|・||New EUR 750 million share buy-back|
|・||Sustainability targets reconfirmed; energy savings target doubled|
raises the outlook for the full year 2007: Operating
profit (before exceptional items) is expected to be EUR
820 million +/- 3% (up from EUR 790 million +/- 3%)
“DSM’s market leading positions and combined technological expertise in Life Sciences and Materials Sciences create a unique portfolio for growth and innovation,” said Feike Sijbesma, Chairman of the Managing Board of DSM, “and this accelerated Vision 2010 strategy gives us the ambition and urgency to capture its potential. By increasing our focus on these specialty areas of our business and freeing up resources for innovation and acquisitions, we believe this program will generate significant future value for our stakeholders.”
conclusions from DSM’s mid-term evaluation of
the Vision 2010 ? Building on Strengths strategy,
originally presented at the annual DSM Analysts
Conference in October 2005, are presented today. The
review continues DSM’s track record of
successful portfolio adjustments and accelerates the
group’s shift to a specialty
Life Sciences and Materials Sciences company, delivering
faster growth, higher margins and improved earnings
At the same time, the review confirms DSM’s three key strategic drivers of market-driven growth and innovation, an increased presence in emerging economies and operational excellence. A number of ambitious new growth objectives have been set, including raising the company’s annual organic sales growth target from 3-5% to more than 5%. Additional shareholder value is expected to be created through a proposed uplift in the dividend per share and a new EUR 750 million share buy-back program.
on Life Sciences and Materials Sciences
Following a fundamental review undertaken across the whole of the group’s business portfolio, DSM has taken the decision to focus on its specialty Life Sciences (Nutrition and Pharma) and Materials Sciences (Performance Materials) businesses. These businesses operate in sectors where DSM has market leading positions and utilize unique technology platforms which combine DSM’s expertise in chemistry, process technology, (white/industrial) biotechnology and materials science.
DSM’s specialty life sciences and materials sciences businesses are serving rapidly growing societal needs, particularly in areas such as improving nutrition, health and the environment and enhancing people’s quality of life. They are global businesses. Their technology platforms can be used across numerous, diverse areas of application which provide multiple opportunities for growth whilst at the same time enabling high levels of sustainability. They also share a number of competences in both technologies and markets where cross fertilization between the units can be fostered, in particular within the areas of biotechnology and biomaterials, enabling DSM to be at the forefront in the creation of novel, bio-based
products from renewable resources. The four Emerging Business Areas (White Biotech, Personalized Nutrition, Biomedical and Specialty Packaging) fit very well in this thrust.
In the Vision 2010 period so far the target of 3-5% sales growth per year has clearly been beaten. DSM is confident that a higher growth target than originally foreseen can be achieved over the remainder of the Vision 2010 period. Therefore, DSM raises the organic sales growth target (in constant currencies) to more than 5% (based on assumed economic scenario).
By 2010, after this transformation of DSM to focus on Life Sciences and Material Sciences, DSM will be a stronger company with higher quality of earnings. DSM will be well positioned for increased ambitions thereafter.
scope for divestment and partnering
Those businesses which do not fit with the strategic thrust will be carved out and divested, during the course of the Vision 2010 period, to new owners for whom there is a stronger strategic fit and under whose ownership they can prosper further. These businesses will be grouped in a new Base Chemicals & Materials cluster and include:
divestments will result in a reduced presence at the
Chemelot site, Geleen (NL).
DSM will review its options how it can best support the further development of that site into a successful industrial park. In addition, DSM will continue to invest in its R&D campus infrastructure on this site.
A partnering strategy will be pursued for DSM’s citric acid interests (currently within Nutrition, with 2007E Sales ~EUR 125 million), which will also be reported in the Base Chemicals & Materials cluster.
The new Base Chemicals & Materials cluster is expected to deliver 2007 sales of approximately EUR 1.5 billion, EBITDA of approximately EUR 200 million and EBIT of about EUR 100 million.
DSM Fibre Intermediates activities (currently within Industrial Chemicals), which provide backward integration for DSM Engineering Plastics and have a strong leadership position, will be reported in a new cluster Polymer Intermediates.
As a result of
the above, DSM will create five
reporting clusters, as follows:
The EBITDA margin
targets of the clusters will be adjusted to reflect their
As part of the evaluation of Vision 2010 ? Building on Strengths the following financial policy has been defined:
|・||The company’s gearing target (defined as net debt / total capital) of 30-40% is confirmed.|
will be allocated along the following priorities:
- capital expenditure (including acquisitions for new business development)
- increased dividends
- share buy-backs
|・||DSM’s dividend policy will be adjusted to reflect the more stable, steadily increasing profitability of its specialty businesses. DSM aims to provide a stable and preferably rising dividend. A 20% dividend increase per ordinary share is to be recommended at the company’s next Annual General Meeting in March 2008.|
|・||A new EUR 750 million share buy-back program will commence in October 2007 with a comparable scheme as in 2006/2007.|
|・||DSM’s weighted average cost of capital (WACC) is 7.5% and the CFROI target (cash flow return on investment) will be 100 base points above WACC (up from the current level of 50 bps above the previous WACC of 8%).|
|・||DSM has adopted a systematic, risk-management oriented hedging strategy, with the objective of hedging approximately 50% of the company’s net US Dollar currency exposure on a rolling annual basis.|
|Total shareholder return (TSR) remains the group’s key performance metric and DSM will continue to target a TSR above the peer group average.|
ambitious Vision 2010 targets
The successful execution of the accelerated Vision 2010 program will result in the continuing evolution of DSM into a specialty life sciences and materials sciences business.
The group will be strongly positioned for growth with the main drivers being delivered from market-driven innovation and an increasing presence in the world’s rapidly developing emerging economies, particularly China, as well as from acquisitions. DSM’s ongoing commitment to Operational Excellence remains firmly in place.
The adoption of this strategy, with its objective of achieving a better quality earnings base from higher margin businesses, has enabled DSM to increase the Vision 2010 targets, as follows:
|Vision 2010||Original Target||New Target|
|Organic sales growth||3-5%||>5%*|
- Performance Materials
- Polymer Intermediates
|Growth from innovation||EUR 1 billion by 2010||EUR 1 billion by 2010|
|Growth in China||USD 1 billion by 2010||USD 1.5 billion by 2010|
|CFROI||WACC + 50 bp||WACC + 100 bp|
|Specialty profile||50-60%||Towards 60%|
|Sustainability||Triple P policy||Double
Other targets confirmed
|Total shareholder return (TSR)||Above
* for the remainder of
the period, based on assumed economic scenario
New bond issue
DSM is considering the refinancing of upcoming debt maturities in the fourth quarter with a new benchmark size Eurobond. A series of meetings with bond investors will be arranged, starting Monday 8 October 2007. The timing of the new issue will be subject to market developments.
Trading Update and Outlook
Trading conditions in some of DSM’s businesses are more favorable than earlier expected. Amongst others price developments in anti-infectives and in some parts of the nutrition business are positive due to a shifting demand-supply balance. DSM expects its operating profit (before exceptional items) for the full year 2007 to be EUR 820 million with an uncertainty of plus or minus 3% (up from EUR 790 million plus or minus 3%).
DSM announces new breakthrough polymer PA4T
Royal DSM N.V. today announces the development of a new polymer which extends the portfolio for high performance engineering thermoplastics. The polymer, described as PA4T, has been developed by DSM Engineering Plastics, the inventor and global market leader in high performance polyamides with Stanyl® 46.
no details of its chemistry have been given, it must be assumed to be closely related to DSM's unique PA46, Stanyl.
The new polymer will answer to market trends for miniaturization and convergence of electronic devices like cell phones and computers. It will assist automakers in continued weight reduction efforts for better fuel efficiency and lower costs. PA4T exhibits an exciting and unique balance of properties including excellent dimensional stability, compatibility with lead free soldering, high stiffness and mechanical strength at elevated temperatures, high melting point, and excellent processability in terms of flow and processing window.
Nico Gerardu, member of DSM’s Managing Board and responsible for the Performance Materials cluster, is proud of the invention: “It is very special that DSM introduces a new polymer to the market. Polymers started to enter the materials arena at the beginning of the 20th century, around the time that DSM was born. Most of the polymers used today were introduced to the market in the ‘30’s till ‘60’s. After 1980 very few new polymers were introduced. PA4T is the first new polymer to be introduced in the new millennium ? which is a true achievement of our research and business people and a true commitment to innovation. This breakthrough innovation fits perfectly with the acceleration of DSM’s strategy Vision 2010 - Building on Strengths as announced today, which involves a strong focus on Life Sciences and Materials Sciences.”
DSM envisions that PA4T materials are highly suitable for electronics applications such as memory card connectors, CPU sockets, high temperature bobbins, and notebook computer memory module connectors, based on its excellent compatibility in lead free surface mount technology and dimensional stability. In automotive markets, DSM expects the material to support new developments in under the hood applications relating to automotive electrical systems, fuel delivery, and cooling components.
DSM has filed patents on the new polymer, developed compounds and held initial investigative trials with market leaders for various end uses. Results to date have been impressive and DSM is currently constructing a market development plant at the Chemelot site in Sittard-Geleen, the Netherlands, which will provide quantities of the polymer for pre-marketing. The market development plant will become operational in the first quarter 2008.
“This is an exciting opportunity for DSM Engineering Plastics and for our customers, who are being driven for higher performance in their applications and lower system costs delivered to their customers. PA4T is a promising complementary product in our portfolio. This development will support green initiatives such as lead free soldering and improved fuel economy. We are committed to moving as quickly as possible to bring this new material, which addresses these needs, to the market and to extend the number of applications where high performance polyamides can be effective," comments Roelof Westerbeek, Global Business Director High Performance Polyamides at DSM Engineering Plastics.
DSM Engineering Plastics
DSM Engineering Plastics is a business group in DSM’s Performance Materials cluster, with sales in 2006 of EUR 1005 million (which number includes the sales of DSM Dyneema) and approximately 1300 employees worldwide. It is one of the world's leading suppliers of engineering thermoplastics offering a broad portfolio of high performance products including Stanyl® PA 46 and Akulon® 6 and 66 polyamides, Arnitel® TPE-E, Arnite® PBT and PET polyesters, Xantar® polycarbonate and Yparex® extrudable adhesive resins. These materials are used in technical components for electrical appliances, electronic equipment and cars, in barrier packaging films as well as in many mechanical and extrusion applications. With Stanyl®, DSM Engineering Plastics is the global market leader in high heat polyamides. Akulon®, Arnite®, Arnitel®, Stanyl®, Xantar® and Yparex® are registered trademarks of DSM Engineering Plastics. Dyneema®, Dyneema Purity® and Dyneema®, the world's strongest fiber™ are trademarks and applications owned by Royal DSM N.V.
DSM invests in development of bio-based materials in China
DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has participated in a USD 20 million financing round in Tianjin Green Bio-Science Co., Ltd (China). The proceeds will be used to build China’s largest manufacturing plant for Polyhydroxyalkanoates (PHA) in the Tianjin Economic Development Area (TEDA).
微生物産生ポリエステル（ポリヒドロキシアルカン酸 PHA) は、バイオマス由来の有機物をある種の微生物に与えることにより得られる脂肪族ポリエステル
The investment is in line with DSM’s ambitions to develop bio-based performance materials to meet customers’ growing needs for improved performance and environmental benefits at competitive costs. PHA offers, in response to the growing market need for eco-friendly solutions, a new biorenewable polymer platform for a broad range of applications from automotive to biomedical and electronics, including multiple forms like fibers, films and foams.
In parallel with the venture investment, DSM and TGBS intend to work together to create new business in bio-based performance materials.
This investment brings the total number of current company participations of DSM Venturing to 20. Venturing forms an integral part of DSM’s open innovation approach, focused on teaming up with innovative players all over the world. The company has earmarked up to EUR 200 million for venturing investments until 2012. China is one of the core regions in the global investment strategy of DSM Venturing.
Babette Pettersen, Vice President New Business Development Performance Materials of DSM, said, “Following earlier announcements on biopolymers, this TGBS investment and intended cooperation complements our ongoing development of bio-based performance materials. This will help to meet the growing market needs for eco-friendly solutions in a range of applications. As PHA is produced through fermentation by micro-organisms, it also offers the opportunity for DSM to extend its competencies both in Life Sciences and Material Sciences to a new family of biopolymers.”
“The investment in Tianjin Green Bio-Science is a further confirmation of DSM’s global venturing strategy, in which China is one of the core regions. Moreover, it shows the company’s commitment and dedication to actively promoting China’s sustainable development initiatives, as one of the important elements in building a strong business position in China,” said Weiming Jiang, President DSM China. “The transition from petroleum-based materials to bio-based materials is a major global trend. With our expertise in biotechnology and in performance materials DSM is excellently positioned to facilitate this transition.”
Mr. Lu Weichuan, General Manager of Tianjin Green Bio-Science Co., Ltd. expressed full confidence in the partnership and said, “Through years of research and development, Tianjin Green Bio-Science has reached a leadership position within China for the production, extraction, processing and application of PHA. In addition to its financial investment in this partnership, DSM will also bring its international experience in life science and materials science. This cooperation will definitely speed up our growth and production of world-class biorenewable plastic products.”
The plant’s construction will commence in Q2 2008, and is expected to start production in early 2009. It will have an annual production capacity of 10,000 tons of PHA.
DSM Venturing is an active investor in emerging companies and Venture Capital Funds in DSM’s strategic growth fields Nutrition, Pharma and Performance Materials. DSM Venturing's mission is to explore emerging markets and technologies in these strategic growth fields in order to enhance DSM's product portfolio and create value. DSM Venturing also plays an active role in the development of several new DSM business opportunities in the so-called emerging business areas Biomedical, Industrial (White) Biotechnology, Specialty Packaging and Personalized Nutrition. For more information about DSM Venturing see www.dsm venturing.com.
About Tianjin Green
Bio-Science Co., Ltd.
Tianjin Green Biosciences Co., Ltd (TGBS), located in the High-Tech Park of Tianjin University in TEDA, Tianjin, is dedicated to developing and producing biodegradable polymers and products. Research demonstrates that the PHAs TGBS developed have excellent biodegradable, processing performance and biocompatibility. Due to its special properties, the PHA could be developed for use of high value added products including high strength fiber, pressure sensitive adhesive, aqueous adhesive, human tissue engineering product, etc., as well as applications in food and commodity packaging, with the potential to substitute 50% petroleum-based plastic in application.